Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ClouDr Group Limited
智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9955)

VOLUNTARY ANNOUNCEMENT IN RELATION TO THE SERVICE COOPERATION AGREEMENT WITH JD HEALTH

This announcement is made by ClouDr Group Limited (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**") on a voluntary basis. The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that recently, the Company entered into a service cooperation agreement with JD Health International Inc. ("**JD Health**", a company listed on the Hong Kong Stock Exchange, stock code: 6618.HK) to expand online sales and service channels for Remifemin® and other P2M pipeline products, providing patients with a more convenient medication purchasing experience and professional full-cycle health management services.

As the largest pharmaceutical e-commerce platform in China, JD Health boasts a substantial user base and extensive platform resources. Meanwhile, as a leading chronic disease management platform in China, the Company possesses a unique pipeline of products and expertise in patient-doctor management. The collaboration between the two parties represents a powerful alliance and allows efficient promotion of high-quality, cost-effective medications.

To the best of the Board's knowledge, information and belief after having made all reasonable enquiries, JD Health is a third party independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). The Company will comply with the Listing Rules and make further announcement(s) on the potential cooperation as and when appropriate. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
ClouDr Group Limited
Kuang Ming
Chairman, Executive Director and
Chief Executive Officer

Hong Kong, November 13, 2025

As at the date of this announcement, the Board comprises Mr. Kuang Ming and Ms. Zuo Yinghui as the executive Directors, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.

* *For identification purpose only*